OBJECTIVE: To compare the effectiveness of clindamycin, trimethoprim-sulfamethoxazole, and β-lactams for the treatment of pediatric skin and soft-tissue infections (SSTIs). METHODS: A retrospective cohort of children 0 to 17 years of age who were enrolled in Tennessee Medicaid, experienced an incident SSTI between 2004 and 2007, and received treatment with clindamycin (reference), trimethoprim-sulfamethoxazole, or a β-lactam was created. Outcomes included treatment failure and recurrence, defined as an SSTI within 14 days and between 15 and 365 days after the incident SSTI, respectively. Adjusted models stratified according to drainage status were used to estimate the risk of treatment failure and time to recurrence. RESULTS: Among the 6407 children who underwent drainage, there were 568 treatment failures (8.9%) and 994 recurrences (22.8%). The adjusted odds ratios for treatment failure were 1.92 (95% confidence interval [CI]: 1.49-2.47) for trimethoprim-sulfamethoxazole and 2.23 (95% CI: 1.71-2.90) for β-lactams. The adjusted hazard ratios for recurrence were 1.26 (95% CI: 1.06-1.49) for trimethoprim-sulfamethoxazole and 1.42 (95% CI: 1.19-1.69) for β-lactams. Among the 41 094 children without a drainage procedure, there were 2435 treatment failures (5.9%) and 5436 recurrences (18.2%). The adjusted odds ratios for treatment failure were 1.67 (95% CI: 1.44-1.95) for trimethoprim-sulfamethoxazole and 1.22 (95% CI: 1.06-1.41) for β-lactams; the adjusted hazard ratios for recurrence were 1.30 (95% CI: 1.18-1.44) for trimethoprim-sulfamethoxazole and 1.08 (95% CI: 0.99-1.18) for β-lactams. CONCLUSIONS: Compared with clindamycin, use of trimethoprim-sulfamethoxazole or β-lactams was associated with increased risks of treatment failure and recurrence. Associations were stronger for those with a drainage procedure.
OBJECTIVE: To compare the effectiveness of clindamycin, trimethoprim-sulfamethoxazole, and β-lactams for the treatment of pediatric skin and soft-tissue infections (SSTIs). METHODS: A retrospective cohort of children 0 to 17 years of age who were enrolled in Tennessee Medicaid, experienced an incident SSTI between 2004 and 2007, and received treatment with clindamycin (reference), trimethoprim-sulfamethoxazole, or a β-lactam was created. Outcomes included treatment failure and recurrence, defined as an SSTI within 14 days and between 15 and 365 days after the incident SSTI, respectively. Adjusted models stratified according to drainage status were used to estimate the risk of treatment failure and time to recurrence. RESULTS: Among the 6407 children who underwent drainage, there were 568 treatment failures (8.9%) and 994 recurrences (22.8%). The adjusted odds ratios for treatment failure were 1.92 (95% confidence interval [CI]: 1.49-2.47) for trimethoprim-sulfamethoxazole and 2.23 (95% CI: 1.71-2.90) for β-lactams. The adjusted hazard ratios for recurrence were 1.26 (95% CI: 1.06-1.49) for trimethoprim-sulfamethoxazole and 1.42 (95% CI: 1.19-1.69) for β-lactams. Among the 41 094 children without a drainage procedure, there were 2435 treatment failures (5.9%) and 5436 recurrences (18.2%). The adjusted odds ratios for treatment failure were 1.67 (95% CI: 1.44-1.95) for trimethoprim-sulfamethoxazole and 1.22 (95% CI: 1.06-1.41) for β-lactams; the adjusted hazard ratios for recurrence were 1.30 (95% CI: 1.18-1.44) for trimethoprim-sulfamethoxazole and 1.08 (95% CI: 0.99-1.18) for β-lactams. CONCLUSIONS: Compared with clindamycin, use of trimethoprim-sulfamethoxazole or β-lactams was associated with increased risks of treatment failure and recurrence. Associations were stronger for those with a drainage procedure.
Authors: Pranavi Sreeramoju; Nabilla S Porbandarwalla; Jorge Arango; Kerry Latham; Daniel L Dent; Ronald M Stewart; Jan E Patterson Journal: Am J Surg Date: 2010-09-15 Impact factor: 2.565
Authors: Steven C Buckingham; Linda K McDougal; Lorene D Cathey; Katha Comeaux; Allen S Craig; Scott K Fridkin; Fred C Tenover Journal: Pediatr Infect Dis J Date: 2004-07 Impact factor: 2.129
Authors: Michael W Ellis; Duane R Hospenthal; David P Dooley; Paula J Gray; Clinton K Murray Journal: Clin Infect Dis Date: 2004-09-02 Impact factor: 9.079
Authors: Michael C Lee; Ana M Rios; Monica Fonseca Aten; Asuncion Mejias; Dominick Cavuoti; George H McCracken; R Doug Hardy Journal: Pediatr Infect Dis J Date: 2004-02 Impact factor: 2.129
Authors: Jessica L Markham; Matthew Hall; Mary Ann Queen; Paul L Aronson; Sowdhamini S Wallace; Dana M Foradori; Gabrielle Hester; Jennifer Nead; Michelle A Lopez; Andrea T Cruz; Russell J McCulloh Journal: Hosp Pediatr Date: 2019-01
Authors: Loren G Miller; Robert S Daum; C Buddy Creech; David Young; Michele D Downing; Samantha J Eells; Stephanie Pettibone; Rebecca J Hoagland; Henry F Chambers Journal: N Engl J Med Date: 2015-03-19 Impact factor: 91.245
Authors: David A Talan; Frank Lovecchio; Fredrick M Abrahamian; David J Karras; Mark T Steele; Richard E Rothman; Anusha Krishnadasan; William R Mower; Rebecca Hoagland; Gregory J Moran Journal: Clin Infect Dis Date: 2016-03-29 Impact factor: 9.079
Authors: Patrick G Hogan; Marcela Rodriguez; Allison M Spenner; Jennifer M Brenneisen; Mary G Boyle; Melanie L Sullivan; Stephanie A Fritz Journal: Clin Infect Dis Date: 2018-01-06 Impact factor: 9.079